NEW YORK — Pfizer Inc. shares ticked up modestly Tuesday as investors weighed fresh positive oncology data against the pharmaceutical giant's flat revenue guidance for 2026 and ongoing pressures from declining COVID-19 product sales.
Pfizer stock (NYSE: PFE) rose to around $27.97 in morning trading, up 20 cents or 0.72% from Monday's close near $27.77, with volume building as the market digested recent clinical successes and the company's long-term pivot toward oncology and obesity. The modest gain came after shares had traded in a relatively tight range in recent sessions, hovering near 52-week highs around $27.94.
